LOW-DOSE ARA-C AS AN ALTERNATIVE THERAPY FOR OLDER PATIENTS WITH AML

被引：0
|
作者：
HEYLL, A [1 ]
AUL, C [1 ]
HEYLL, U [1 ]
FISCHER, JT [1 ]
SCHNEIDER, W [1 ]
机构：
[1] UNIV DUSSELDORF,KLIN A,MED KLIN & POLIKLIN,D-4000 DUSSELDORF,FED REP GER
来源：
BLUT | 1985年 / 51卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：163 / 163
页数：1
相关论文
共 50 条
  • [1] LOW-DOSE ARA-C AS MAINTENANCE TREATMENT IN AML
    CATALANO, L
    FONTANA, R
    SELLERI, C
    DEROSA, G
    ROTOLI, B
    HAEMATOLOGICA, 1989, 74 (04) : 412 - 413
  • [2] CONTINUOUS LOW-DOSE INFUSIONS OF ARA-C IN MANAGEMENT OF PATIENTS WITH AML
    POTTER, CG
    BUNCH, C
    PIPPARD, MJ
    ROWELL, AC
    BRITISH JOURNAL OF CANCER, 1978, 38 (01) : 181 - 181
  • [3] Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
    Dennis, Mike
    Thomas, Ian F.
    Ariti, Cono
    Upton, Laura
    Burnett, Alan K.
    Gilkes, Amanda
    Radia, Rohini
    Hemmaway, Claire
    Mehta, Priyanka
    Knapper, Steven
    Clark, Richard E.
    Copland, Mhairi
    Russell, Nigel
    Hills, Robert K.
    BLOOD ADVANCES, 2021, 5 (24) : 5621 - 5625
  • [4] The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome
    A K Burnett
    R K Hills
    A Hunter
    D Milligan
    J Kell
    K Wheatley
    J Yin
    M-F McMullin
    P Cahalin
    J Craig
    D Bowen
    N Russell
    Leukemia, 2011, 25 : 1122 - 1127
  • [5] The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome
    Burnett, A. K.
    Hills, R. K.
    Hunter, A.
    Milligan, D.
    Kell, J.
    Wheatley, K.
    Yin, J.
    McMullin, M-F
    Cahalin, P.
    Craig, J.
    Bowen, D.
    Russell, N.
    LEUKEMIA, 2011, 25 (07) : 1122 - 1127
  • [6] Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia
    Dennis, Mike
    Russell, Nigel
    Hills, Robert K.
    Hemmaway, Claire
    Panoskaltsis, Nicki
    McMullin, Mary-Frances
    Kjeldsen, Lars
    Dignum, Helen
    Thomas, Ian F.
    Clark, Richard E.
    Milligan, Don
    Burnett, Alan K.
    BLOOD, 2015, 125 (19) : 2923 - 2932
  • [7] INTERMEDIATE-DOSE ARA-C AND IDARUBICIN FOLLOWED BY LOW-DOSE ARA-C IS PARTICULARLY EFFECTIVE IN UNMAINTAINED RELAPSED AML
    MUUS, P
    DEWITTE, T
    RAEMAEKERS, J
    BLOOD, 1994, 84 (10) : A146 - A146
  • [8] MORE ON LOW-DOSE ARA-C
    BERNARDESCHI, P
    BONECHI, I
    HAEMATOLOGICA, 1986, 71 (01) : 86 - 86
  • [9] LOW-DOSE ARA-C FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES
    POWELL, BL
    CAPIZZI, RL
    JACKSON, DV
    RICHARDS, F
    MUSS, HB
    LYERLY, ES
    ROSENBAUM, DL
    CONNELLY, RA
    BUSS, DH
    BEARDEN, JD
    HUTCHESON, JR
    CRAIG, JB
    ZEKAN, PJ
    CRUZ, JM
    WHITE, DR
    LEUKEMIA, 1988, 2 (03) : 153 - 156
  • [10] LOW-DOSE ARA-C THERAPY FOR ACUTE MYELOGENOUS LEUKEMIA IN ELDERLY PATIENTS
    POWELL, BL
    CAPIZZI, RL
    MUSS, HB
    BEARDEN, JD
    LYERLY, ES
    ROSENBAUM, DL
    MORGAN, TM
    RICHARDS, F
    JACKSON, DV
    WHITE, DR
    NELSON, EC
    BUTLER, WM
    ZEKAN, PJ
    CRUZ, JM
    COOPER, MR
    BUSS, DH
    SPURR, CL
    LEUKEMIA, 1989, 3 (01) : 23 - 28
12345